Recent Price Movement and Market Context
On 24 Nov 2025, Kopran's stock price touched Rs.126.6, the lowest level recorded in the past year. This price point comes after two consecutive days of declines, during which the stock has returned -5.52%. The daily change on the latest trading session was -1.71%, underperforming the Pharmaceuticals & Biotechnology sector by approximately -1.68%. Kopran is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward pressure.
In contrast, the broader market has shown resilience. The Sensex opened 88.12 points higher and was trading at 85,455.79, a 0.26% gain on the day. The index is approaching its 52-week high of 85,801.70, just 0.4% away, and has recorded a 2.69% gain over the past three weeks. Mega-cap stocks have been leading this positive trend, with the Sensex trading above its 50-day moving average, which itself is positioned above the 200-day moving average, signalling a bullish market environment.
Long-Term and Recent Performance Analysis
Kopran's one-year performance shows a return of -42.35%, a stark contrast to the Sensex's 8.01% gain over the same period. The stock's 52-week high was Rs.236.1, highlighting the extent of the decline to the current low. Over the last three years, the stock has also underperformed the BSE500 index across multiple time frames, including the last three months and one year.
Financially, Kopran has faced challenges in both top-line and bottom-line metrics. Net sales have shown a contraction of -22.2%, with the company reporting negative results for five consecutive quarters. The latest quarterly profit after tax (PAT) stood at Rs. -9.92 crores, reflecting a fall of -234.4%. Operating profit has declined at an annual rate of -11.79% over the past five years, indicating subdued growth trends.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Profitability and Efficiency Metrics
Kopran's return on capital employed (ROCE) for the half-year period is reported at 5.38%, one of the lowest in recent times. The operating profit to interest ratio for the quarter is at -2.53 times, indicating that operating profits are insufficient to cover interest expenses. These figures highlight the pressure on the company's profitability and capital efficiency.
Despite these challenges, Kopran maintains a relatively low average debt-to-equity ratio of 0.23 times, which suggests limited leverage compared to many peers in the Pharmaceuticals & Biotechnology sector. The enterprise value to capital employed ratio stands at 1.2, reflecting an attractive valuation relative to the company's capital base.
However, the stock is trading at a discount compared to the average historical valuations of its sector peers. Over the past year, profits have declined by -66.7%, further underscoring the financial strain experienced by the company.
Shareholding and Market Interest
Domestic mutual funds hold a minimal stake in Kopran, accounting for only 0.01% of the company’s shares. Given the capacity of these funds to conduct detailed research and due diligence, this small holding may reflect a cautious stance towards the stock’s current valuation and business outlook.
Holding Kopran from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Financial Indicators
To summarise, Kopran’s financial indicators over recent periods reveal a company facing significant headwinds. The stock’s decline to Rs.126.6 marks a new 52-week low, reflecting the cumulative impact of subdued sales, negative quarterly results, and pressure on profitability metrics. While the company’s low leverage and valuation discount may be noted, the overall performance metrics indicate a challenging environment for the stock within the Pharmaceuticals & Biotechnology sector.
Meanwhile, the broader market environment remains positive, with the Sensex near its yearly highs and supported by strong performances from mega-cap stocks. This divergence highlights the specific difficulties Kopran is encountering relative to the general market trend.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
